ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1
First Claim
Patent Images
1. An isolated antibody or antibody fragment which binds to human PD-1 comprising:
- a. at least one CDR selected from the group consisting of SEQ ID NOs;
9, 10, 11, 15, 16 and 17, or a variant of any said sequence; and
/orb. at least one CDR selected from the group consisting of SEQ ID NOs;
12, 13, 14, 18, 19 and 20, or a variant of any said sequence.
4 Assignments
0 Petitions
Accused Products
Abstract
Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed.
-
Citations
19 Claims
-
1. An isolated antibody or antibody fragment which binds to human PD-1 comprising:
-
a. at least one CDR selected from the group consisting of SEQ ID NOs;
9, 10, 11, 15, 16 and 17, or a variant of any said sequence; and
/orb. at least one CDR selected from the group consisting of SEQ ID NOs;
12, 13, 14, 18, 19 and 20, or a variant of any said sequence. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
-
9. An isolated antibody or antibody fragment which competes for a binding epitope on PD-1 with antibody hPD-1.08A or antibody hPD-1.09A, and has a one of the following characteristics:
-
a. binds human PD-1 with a KD of about 100 pM or lower; b. binds human PD-1 with a KD of about 30 pM or lower; c. binds to human PD-1 with about the same KD as an antibody having a heavy chain comprising the amino acid sequence of SEQ ID NO;
31 and a light chain comprising the amino acid sequence of SEQ ID NO;
32;d. binds to human PD-1 with about the same KD as an antibody having a heavy chain comprising the amino acid sequence of SEQ ID NO;
31 and a light chain comprising the amino acid sequence of SEQ ID NO;
33;e. binds to human PD-1 with a kassoc of about 7.5×
105 1/M·
s or faster;f. binds to human PD-1 with a kassoc of about 1×
106 1/M·
s or faster;g. binds to human PD-1 with a kassoc of about 2×
10−
5 1/s or slower;h. binds to human PD-1 with a kdissoc of about 2.7×
10−
5 1/s or slower;i. binds to human PD-1 with a kdissoc of about 3×
10−
5 1/s or slower;
orj. blocks binding of human PD-L1 or human PD-L2 to human PD-1 with an IC50 of about 1 nM or lower.
-
-
10. An isolated polynucleotide encoding an antibody or antibody fragment which binds to human PD-1, wherein the antibody or antibody fragment comprises
a. at least one CDR selected from the group consisting of SEQ ID NOs: - 9, 10, 11, 15, 16 and 17; and
/orb. at least one CDR selected from the group consisting of SEQ ID NOs;
12, 13, 14, 18, 19 and 20. - View Dependent Claims (11, 12, 13, 14)
- 9, 10, 11, 15, 16 and 17; and
-
15. A composition comprising an antibody or antibody fragment thereof in combination with a pharmaceutically acceptable carrier or diluent, wherein said antibody is h409A11, h409A16 or h409A17.
-
16. A method of increasing the activity of an immune cell, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antibody fragment which binds to human PD-1, wherein the antibody or antibody fragment comprises
a. at least one CDR selected from the group consisting of SEQ ID NOs: - 9, 10, 11, 15, 16 and 17; and
/orb. at least one CDR selected from the group consisting of SEQ ID NOs;
12, 13, 14, 18, 19 and 20. - View Dependent Claims (17, 18, 19)
- 9, 10, 11, 15, 16 and 17; and
Specification